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Background: Asystasia gangentica (A. gangetica) belongs to the family Acanthaceae. It is used to treat hypertension,
rheumatism, asthma, diabetes mellitus, and as an anthelmintic in South Africa, India, Cameroun, Nigeria, and Kenya
respectively. It has also been reported to inhibit the angiotensin I converting enzyme (ACE) in-vitro. Therefore, the
aim of this study is to investigate the in-vivo effect of aqueous leaf extract (ALE) of A. gangetica on the blood
pressure (BP) and heart rate (HR) in anaesthetized male spontaneously hypertensive rats (SHR); and to elucidate
possible mechanism(s) by which it acts.
Methods: The ALE of A. gangetica (10–400 mg/kg), angiotensin I human acetate salt hydrate (ANG I, 3.1–100 μg/kg)
and angiotensin II human (ANG II, 3.1–50 μg/kg) were administered intravenously. The BP and HR were measured
via a pressure transducer connecting the femoral artery to a Powerlab and a computer for recording.
Results: A. gangetica significantly (p<0.05), and dose-dependently reduced the systolic, diastolic, and mean
arterial BP. The significant (p<0.05) reductions in HR were not dose-dependent. Both ANG I and ANG II increased
the BP dose-dependently. Co-infusion of A. gangetica (200 mg/kg) with either ANG I or ANG II significantly (p<0.05)
suppressed the hypertensive effect of both ANG I and ANG II respectively, and was associated with reductions
in HR.
Conclusions: A. gangetica ALE reduced BP and HR in the SHR. The reduction in BP may be a result of actions of
the ALE on the ACE, the ANG II receptors and the heart rate.
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aldosterone systemBackground
A great number of plants have been used throughout
the world from time immemorial for the prevention and
cure of sickness [1]. About eighty percent of the active
compounds of drugs used for the treatment of cardio-
vascular conditions are extracted from medicinal plants,
e.g. foxglove (digitalis lanata), Allium sativum (garlic),
camphor and Adonis vernalis [1-3].
Drugs used for the treatment of hypertension include
angiotensin converting enzyme inhibitors (ACEIs), alpha1
adrenoceptor blockers, calcium channel blockers, angiotensin* Correspondence: pmugabo@uwc.ac.za
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distribution, and reproduction in any mediumII (ANG II) receptor antagonists, diuretics and beta
adrenoceptor blockers [4-7]. Most of these drugs are ex-
pensive, and in many cases, none of them can control
hypertension on its own. Consequently, combination
therapy is often required [5,6]. However, combination
therapy (polytherapy) has its drawbacks, such as in-
creased risk of drug interactions, side effects and poor
compliance [8-10]. These necessitate continuous search
for novel agents which are more effective, cheaper,
come with less side-effects, and preferably used alone.
Asystasia gangentica (A. gangetica) belongs to the fam-
ily Acanthaceae [11,12]. There are eight species native to
Southern Africa, and notably, the Kwazulu Natal prov-
ince of South Africa [12]. A. gangetica is used to treat
asthma in Nigeria [13], as an antihelmintic in Kenyantral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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India [15]. It has also been suggested to exhibit antihy-
pertensive effects through inhibition of ACE in-vitro
[12]. Therefore, the aim of this study was to evaluate the
effect of ALE of A. gangetica on the blood pressure (BP)
and heart rate (HR) in spontaneously hypertensive rats
(SHR), and also investigate if inhibition of the ACE or
the ANG II receptor mediates its effect in-vivo.
Methods
Study design
The study was designed as an in- vivo experimental model
assessing the effects of A. gangetica on BP and HR in
male SHR.
Collection and preparation of plant material
A. gangetica plants were obtained from Newplant nursery
in George, Western Cape, South Africa (SA), in March
2009. A sample of the plant was deposited at the Univer-
sity of the Western Cape (UWC) herbarium for identifica-
tion and authentication by the taxonomist. It was
registered under the voucher number 3469. Fresh leaves
(1314.27 g) were picked from plants and washed twice
with distilled water. Leaves were permitted to dry com-
pletely in a room where the temperature was maintained
at 23°C for a period of 14 days. Dried leaves (967 g) were
then pulverized to a fine powder (738 g) using a Hammer
mill and stored in airtight glass containers.
Aqueous extraction of plant material
A Soxhlet apparatus was used to extract the active com-
pounds from 738 g powder over 48 hours. A Soxhlet
thimble was constructed with glass fibre. Fine powder of
the A. gangetica was wetted with distilled water, and
placed between two layers of glass fibre (used as a bar-
rier to prevent powder from passing into the extract).
Distilled water (400 ml) was placed in a round bottom
flask and connected together along with the reflux con-
denser. A heating element was used to supply sufficient
heat to boil the distilled water. After extraction, the
remnant of the crude plant material was discarded. The
aqueous extract was then placed in a deep freezer for a
period of 72 hours and transferred to a freeze drier for a
period of 72–96 hours to produce a dry powder ready
for reconstitution and administration. A powder weigh-
ing 179 g was obtained.
Materials and equipments used in the extraction process
of the plant
The materials and equipments used for plant extraction
are of standard analytical grade, and include an oven,
scissors, weighing balance, glass fibre, Soxhlet extractor,
rotovapour (Bachi Rotavapor R200, Switzerland), freeze-
drier (Virtis FreezeMobile 12SL, SA), 0.45 μm filterpaper (Schleicher & Schuell MicroScience, SA) and a −85°C
freezer (Snijder Scientific, SA).
Animals
Healthy male SHR weighing 250–400 g and aged less
than 4 months old were used. The SHR were obtained
from the Animal Unit of the University of Cape Town,
Cape Town (CPT), SA; housed in the animal room of
the School of Pharmacy, UWC; and allowed feed and
water ad-libitum. The animal room temperature was
kept at 24°C, with a 12:12-h light–dark cycle.
Materials and equipments used in the in- vivo
experiments
BP transducer (AD Instruments, CPT, SA), BP amplifier
(ML117 AD Instruments, CPT, SA), PowerLab 4/20 T
(AD Instruments, Lasec, CPT, SA), computer desktop
unit, temperature probe (AD Instruments, Lasec, CPT,
SA), Chart 5.0 for Windows software (AD Instruments,
Lasec, CPT, SA), Ascor AP 22 syringe pump (United
Scientific, CPT, SA), heated rat operating table (Bio-
Science, CPT, SA), overhead lamp, bulldog clamps,
0.5 mm (arterial and venous) cannula, three-way tap,
syringe, threads, oxygen mask, surgical scissors and
cotton wool.
Chemicals and drugs used in the in-vivo experiments
Sodium chloride (Adcock Ingram, SA), dimethyl sulfoxide
(DMSO) (Merck Chemicals, SA), 0.1% heparin sodium
(1000 iu/ml, Intramed, SA), 6% sodium pentobarbitone
(Kyron Laboratories, Johannesburg, SA). 0.9% Sodium
chloride [16] and/or DMSO [17], were respectively used
as vehicle to obtain homogenous dilution of A. gangetica,
heparin, and the unknown drug. All drugs, except where
otherwise indicated, were purchased from Sigma Aldrich,
SA. ANG I and ANG II which have potential antagonistic
effect to that of A. gangetica, were used as negative con-
trols of A. gangetica [6,7,18]. Fresh solutions were made at
the beginning of each experiment. Chemicals, after having
been diluted were kept in ice during the course of the ex-
periment to keep them stable.
Animal preparation and recording of experimental
parameters assessed
After the induction of anesthesia with sodium pentobar-
bitone (40 mg/kg) intraperitoneally, the rat was placed
in a supine position on a heated operating table to main-
tain the temperature of the body temperature at ±37°C.
A temperature probe was inserted into the rectum and
used to measure the core temperature via the amplifier
connected to the PowerLab® and monitored with a com-
puter throughout the experiment. Tracheotomy was
performed and a tube placed in the trachea for easy
breathing. Rats were supplied with oxygen through a
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rounding the tracheal cannula rich in oxygen. The exter-
nal jugular vein and the femoral artery were cannulated
with catheters containing normal saline/heparin solution
in the ratio of 9 ml to 1 ml, for the intravenous infusion
of known drugs and/or the ALE of A. gangetica. In ex-
periments where A. gangetica was co-administered with
a control drug, both external jugular veins were cannu-
lated for simultaneous intravenous administration. One
of the femoral arteries was cannulated for measurement
of arterial BP [19]. BP was measured as systolic pressure
(SBP), diastolic pressure (DBP), and mean arterial pressure
(MAP). Both BP and HR were monitored continuously on
a computer running the Chart 5 software (AD Instruments,
Lasec CPT, SA) through a BP transducer linking the arterial
cannula to a PowerLab® via a BP amplifier. Randomized
doses of drugs and extract were administered during
the study.
Dissolution and infusion of drugs
All drugs and plant extract were dissolved in 0.9% NS
and administered per rat body weight in a volume not
higher than 0.5 ml per dose. DMSO (2 to 3 drops) was
added to the plant extracts for homogenous dilution and
filtered before administration. Drugs were infused at a
rate based on the body weight and dose over 3 minutes
using an Ascor AP 22 syringe pump. The results were
recorded within 3 minutes and drugs flushed with 0.5
ml normal saline. The BP was allowed to stabilize for 10
to 15 minutes, before further doses were infused. Six rats
were used for each set of experiments.
Experimental protocol
Time zero (0) to twenty (20) minutes, the SHR was col-
lected from the animal room and anaesthetized. While
waiting for the anesthesia to take effect, all equipments
were checked to see if they are properly set up. Cathe-
ters were heparinised. Tracheal tube was inserted into
the trachea and the cannulation of the jugular vein and
femoral artery done. Subsequently, the recording of the
experimental parameters began.(a)
Figure 1 Effect of A. gangentica on BP (a) and HR (b). Values are presenTime twenty one (21) to forty (40) minutes, the animal
was allowed to recover from the surgical procedure.
Drugs and/or extract to be administered were diluted.
Time forty one (41) minutes, the animal was stable
and the first dose infused.
Time forty five (45) to sixty (60) minutes, flushing was
done, followed by recovery of the animal from drug ef-
fect, until initial base line was reached. Subsequent doses
were then infused using the same procedure as that of
the first dose.Experimental conditions of the animals
To ascertain that the haemodynamic, respiratory and
metabolic conditions of the rats were stable during the
course of experiments, initial recordings of the cardio-
vascular parameters (SBP, DBP, MAP and HR) to be
assessed during the study were done in a separate group
of control SHRs over 3 hours, time much longer than
the one needed for each experiment. During that period,
no drug or plant extract was administered to the animal.
Furthermore, in randomly selected rats, arterial blood
sample (10 μl) was taken at the beginning (just after sur-
gical preparation of the animal), and at the end of each
experiment. Samples obtained were immediately sent in
ice pack to PathCare Laboratory (Vet laboratory, Bellville,
SA) for arterial blood gaz tests.Statistical analysis
The results obtained are presented as mean values (±
SEM). Statistical significance between means was calcu-
lated using the Student’s t-test and p value <0.05 was
considered significant.Ethics considerations
The study was approved by the ethics committee of
the UWC (Ethics approval reference number 09/9/5)
and was conducted according to the UWC rules and
regulations in terms of animal experiments; and the
European Community guidelines (EEC Directive of
1986; 86/609/EEC).(b)
ted as mean ±. SEM. * indicates statistical significance.
(a) (b)
Figure 2 Effect of angiotensin I on BP (a) and HR (b). Values are presented as mean ±. SEM. * indicates statistical significance.
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Experimental conditions
No statistically significant difference was observed in the
SBP, DBP, MAP, HR, respiratory rate and arterial blood
gaz test results during 3 hours the experiments were
conducted.
Effect of A.gangetica on BP and HR in SHR
A. gangetica (10–400 mg/kg) significantly (<0.01), and
dose-dependently decreased the maximum BP values ob-
tained when compared to their respective values at baseline.
A. gangetica also produced significant (<0.05) reductions in
HR which were not dose-dependent (Figure 1).
Effect of angiotensin I on the BP and HR in SHR
ANG I (3.1–100 μg/kg) significantly (<0.01), and dose-
dependently increased the maximum BP values obtained(a) (b
(c) (d
Figure 3 Effect of ANG I co-infused with A. gangetica on the SBP (a), D
* indicates statistical significance.when compared to their respective values at baseline.
ANG I only produced significant (<0.05) change in HR
at the 3rd and 2nd highest doses (25 and 50 μg/kg re-
spectively, Figure 2).Effect of angiotensin I co-infused with A.gangetica on BP
and HR in SHR
The effects of ANG I (3.1 - 100 μg/kg) on the SBP, DBP,
and MAP was significantly (p<0.001) inhibited by co-
infusion with A. gangentica (200mg/kg). The effect
of ANG I on the HR was also significantly inhibited by
A.gangetica (Figure 3).Effect of angiotensin II on BP and HR in SHR
ANG II (3.1 – 50.0 μg/kg) significantly increased the SBP,
DBP, and MAP in a dose-dependent fashion (Figure 4).)
)
BP (b), MAP (c), and HR (d). Values are presented as mean ± SEM.
(a) (b)
Figure 4 Effect of angiotensin II on BP (a) and HR (b). Values are presented as mean ± SEM. * indicates statistical significance.
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on the BP and HR in SHR
As shown in Figure 5, co-administration of A. gangetica
(200 mg/kg) and ANG II (3.1 – 50.0 μg/kg), significantly
(p<0.01) decreased the hypertensive effect of ANG II on
the SBP, MAP and DBP, as well as its tachycardic effect.
Discussion
Effect of Asystasia gangetica on the blood pressure and
heart rate
The results obtained in this study demonstrate that the
ALE of A. gangetica decreases the BP in a dose dependent
manner in SHR. The hypotensive effect observed (Figure 1)
is concordant with the previous findings of Ramesar et al.
[12] that both aqueous and methanol extracts of A. gange-
tica exhibited ACE inhibitory activity of 20% and 51% re-
spectively in-vitro.(a) (
(c) (
Figure 5 Effect of ANG II co-infused with A. gangetica on the SBP (a),
* indicates statistical significance.Effect of angiotensin I on the blood pressure and
heart rate
The increase in BP is due to the direct vasoconstrictory
actions of ANG II produced from ANG I in the presence
of ACE in-vivo [20,21]. Meanwhile, the increase in HR is
due to significant potentiation of the sympathetic activ-
ity, as well as a direct excitatory action in the heart pro-
duced by high levels of ANG II [18,22-27]. The decrease
in the effect of ANG I on the HR at the dose ≥ 100 μg/kg
may simply be down to Ang II shifting the operating ‘set-
point’ for the regulation of sympathetic outflow to a higher
BP [24,28].
Is the hypotensive effect of A.gangetica mediated by the
inhibition of ACE?
The significant reductions in SBP, DBP and MAP pro-
duced by co-infusing the ALE of A. gangetica with ANGb)
d)
DBP (b), MAP (c), and HR (d). Values are presented as mean ± SEM.
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with infusing ANG I alone (Figure 2) can be attributed
to A. gangetica inhibiting the conversion of ANG I into
ANG II, a powerful vasoconstrictor [29-32]. The signifi-
cant reductions in HR observed with the co-infusion of
A. gangetica with increasing doses of ANG I (Figure 3),
as opposed to the absence of change, or even significant
increases observed at some doses with the infusion of
ANG I alone (Figure 2), could be attributed to lesser
quantities of ANG II being produced. Since the dose of
A. gangetica is fixed, it is expected that less ANG II can
be produced at the lower doses of ANG I, while more
ANG II can be formed at the higher doses.
Are angiotensin II receptors involved in the mechanism of
action of Asystasia gangetica?
ANG II significantly increased the BP (Figure 4), due to
the activation of ANG II receptors (AT IA) in the vascu-
lar smooth muscle cells, resulting in increased vasocon-
striction, decreased renal blood flow and renal tubular
sodium re-uptake, increased aldosterone and vasopressin
secretion [30-36]. The co-administration of the ALE of
A. gangetica with ANG II (Figure 5) significantly inhib-
ited the effect of ANG II alone (Figure 4) on BP. This
antihypertensive effect was associated with significant re-
ductions in HR. This gives more credence to the opinion
that A. gangetica contain chemical compounds, which
act by blocking the actions of ANG II at its various re-
ceptors mentioned above.
Limitations of the study
The angiotensin II (AT1) receptor mediates all of the
known physiological actions of ANG II in the cardiovas-
cular, renal, neuronal, endocrine, hepatic and other tar-
get cells [29,33,37-39]. Therefore, it is important to
investigate the specific action (s) of the crude ALE, and
its constituents at each target cell, as well as, the in-
volvement of the alpha-1, beta-1, and presynaptic alpha-2
adrenoceptors; cholinergic receptors and calcium chan-
nels in the mechanism of action of A. gangetica.
Conclusions
A. gangetica decreases the blood pressure and heart rate
in SHR. This action might be secondary to inhibition of
ACE and the ANG II receptors. It may also involve a
direct inhibitory action on the heart muscle.
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